Keyphrases
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
100%
Urokinase-type Plasminogen Activator
44%
Patient-reported Outcomes
26%
Non-small Cell Lung Cancer (NSCLC)
25%
Epidermal Growth Factor Receptor
25%
Overall Survival
24%
Vascular Endothelial Growth Factor
23%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
22%
Poor Prognosis
19%
Angiogenesis
19%
Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events
18%
Non-small Cell Lung Cancer Patients
18%
Symptomatic Toxicity
18%
Phase II Trial
17%
Tumor Cells
16%
Lung Cancer Tissue
16%
Prognostic Value
16%
Pharmacology, Toxicology and Pharmaceutical Science
Urokinase Receptor
65%
Non Small Cell Lung Cancer
44%
Malignant Neoplasm
43%
Overall Survival
33%
Neoplasm
31%
Urokinase
29%
Epidermal Growth Factor Receptor
25%
Receptor
21%
Progression Free Survival
20%
Adverse Event
19%
Vasculotropin Receptor 2
19%
Phase II Trials
17%
Chemotherapy
16%
Lung Cancer
16%
Medicine and Dentistry
Urokinase Receptor
29%
Non Small Cell Lung Cancer
29%
Patient-Reported Outcome
29%
Adverse Event
17%
